Kondracki Celej advised ff Venture Capital and NanoGroup S.A. on their investment in Auxilius Pharma, which has successfully closed a $4 million (PLN 15 million) financing.

🎯 Kondracki Celej had the pleasure of advising ff Venture Capital and NanoGroup S.A. on their investment in Auxilius Pharma, which has successfully closed a $4 million (PLN 15 million) financing round to accelerate the development of its flagship Value Added Medication, AUX-001, for chronic stable angina.

📈 The round brings together ff Venture Capital, acting on behalf NanoGroup S.A. and NCBR Investment Fund ASI S.A. marking a significant milestone not only for Auxilius Pharma but also for the broader Polish and European biotech ecosystem. The capital will enable the company to advance AUX-001 into the crucial Phase 1b clinical trial, opening the path toward a partnering process focused on the U.S. market.

⚖️ Kondracki Celej advised ff Venture Capital on all legal aspects of the transaction. The transaction was led by Arek Klejnowski with support from Gabriela Lewicka under the supervision of Rafał Celej.

It’s a pleasure to support investments that drive meaningful medical innovation and contribute to building a strong, integrated biotech landscape in Poland and beyond.